Kornimate/medical-research-clean huggingface dataset:
effects of virtual reality in pediatric burn patients

Conditions: Burns Elbows; Pediatric ALL

Summary: the aim of this randomized controlled trial is to find the effectiveness of virtual reality as an adjunctive to transverse friction massage in pediatric burn patients for reducing pain, anxiety and enhancing elbow range of motion.

a burn injury is damage to the skin or other body parts caused by heat, chemicals, electricity, radiation, or friction.pain or discomfort, redness and swelling, blistering, peeling skin, scarring , difficulty breathing, shock in cases of severe burn, fever as a complication of burn, anxiety and depression are some main signs and symptoms after burn injuries. upper limb burn injuries are more common as compared to lower limb , trunk or head and neck. physical therapy plays an important role in reducing pain and improving range of motion and prevention of contractures formation after burn injuries. virtual reality training (vr) uses a computer-generated simulation of a three-dimensional environment that can be interacted with in a seemingly real or physical way. in the context of burn injuries, vr can be used as a distraction technique during wound care procedures or as an adjunct to pain management, and reduction of anxiety level. transverse friction massage therapy is a cyriax technique , is applied by the fingers directly to the lesion and transverse to the direction of fibers.pressure is applied with the ball of the practitioners thumb or fingers to the patient's skin or muscles. friction massage applied correctly will quickly result in analgesic effect over the treated area. friction prevents the adhesion formations as a result leads to improvement of range of motion , prevention of contractures formation as well as pain relief.

Eligibility criteria:
inclusion criteria: * willingly participated in the study. * age group:6-18. * gender: both male and female * acute burn injuries of elbow region (grade 2) * superficial wounds healing phase( 5-10) days * tbsa is less than 20% exclusion criteria * motion sickness * history of seizure activity * burns on body region that impede use of vr equipment (ears, eyes, head) * deep burn (grade 3,4) * fractures

Keywords: virtual reality pediatric burn patients, transverse friction massage elbow burn injuries
study of lamotrigine treatment of affective instability in borderline personality disorder

Conditions: Borderline Personality Disorder

Summary: this study investigates the hypothesis that instability in mood in patients with borderline personality disorder will respond the mood stabilizing medication lamotrigine.

affective instability is one of the most prominent symptoms in borderline personality disorder. currently there are no prospective studies of treatment of this symptom with mood stabilizing medications. this study examines the effectiveness of lamotrigine compared to placebo in reducing emotional instability of several types in borderline patients. the types of emotional instability studied involve anger, anxiety, depression, and elation. subjects entering this 12 week study will be blind to whether they are receiving active medication or placebo. they will be asked to report levels of instability in their mood on a weekly basis. they will also be asked weekly to rate the intensity of other symptoms of borderline personality disorder symptoms, such as unstable relationships, self-harm, and impulsive behaviors.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of borderline personality disorder with high levels of emotional instability exclusion criteria: * clinical diagnosis of bipolar disorder * clinical diagnosis of psychiatric disorder related to general medical condition * clinical diagnosis of substance abuse disorder within the last 60 days * clinical diagnosis of psychotic disorder * previous treatment with lamotrigine * pregnancy or nursing * currently hospitalized * active suicidal or homicidal ideation

Keywords: affective lability borderline personality disorder pharmacotherapy
prediction model for the recanalization outcome evaluation of ischemic stroke using multimodal ct

Conditions: Stroke, Acute

Summary: prediction model for the recanalization outcome evaluation of ischemic stroke using multimodal ct (protect) study was a multicenter prospective observational study that recruited patients from 13 centers located in 10 provinces across china. the study was to assess the effects of novel imaging biomarkers/ imaging patterns based on multimodel ct for patients selection and outcome prediction in acute ischemic stroke.

patients patients with cerebral ischemia symptoms of anterior circulation or posterior circulation onset in 24 hours were included. a neurological evaluation (modified rankin scale and nihss); physical examination, including measurement of weight (kg) and vital signs (supine systolic and diastolic blood pressure); time from symptom onset to enrollment were recorded. imaging protocols: ct scan protocols: non-contrast computed tomography(ncct) , computed tomography angiography(cta), computed tomography perfusion(ctp) contrast agent: cta: omniscan 40-50ml, 5ml/s; saline solution 50ml, 5ml/s ctp: omniscan 50ml, 5ml/s; saline solution 50ml, 5ml/s imaging evaluation: cta was reviewed and stenosis or occlusive lesions were identified. parameter maps including cerebral blood flow, cerebral blood volume, mean transit time, the time to the maximum of the residue function derived from ctp were processed by the software rapid to quantitatively assess infarct core volume and mismatch. multiphase cta was extracted from ctp to evaluate the collateral circulation. treatment: intravenous recombinant tissue plasminogen activator(rtpa), endovascular therapy, and conventional treatment including neuroprotection, anti-platelet, and statin according to the guideline. follow up: modified rankin scale(mrs) was obtained at 90 days after symptom onset. an imaging follow-up was also recommended within 30 days after symptom onset.

Eligibility criteria:
inclusion criteria: * cerebral ischemic sympton with onset in 24 hours * all ct examination performed according to study protocol * signed informed consent obtained from the patient or patient's legally authorized representative exclusion criteria: * acute intracranial hemorrhage * pre-existing medical, the neurological, or psychiatric disease that would confound the neurological, functional, or imaging evaluations * pregnancy * known allergy to iodine previously refractory to pretreatment medications * renal failure (serum creatinine \> 2.0 or glomerular filtration rate \< 30) * history of severe kidney disease as an adult, including tumor or transplant surgery, or family history of kidney failure * severe cardiac insufficiency

Keywords: ischemic stroke ctp cta
a study to evaluate remicade (infliximab) in moderate-to-severe chronic plaque psoriasis in the middle eastern population (study p04528)

Conditions: Psoriasis

Summary: middle eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered infusions of infliximab (remicade) at 5 mg/kg of body weight at weeks 0, 2, 6, 14, and 22. the safety and efficacy of infliximab monotherapy will be evaluated.


Eligibility criteria:
inclusion criteria: * 18 years or older, either gender, and any race. * psoriasis affecting \>=5% of body surface, pasi score \>=10 (maximum score 72). * history of plaque psoriasis for \>6 months. * informed written consent. * refractory to other anti-psoriasis agents (topical corticosteroids, phototherapy uva \[puva\], or systemic therapy). * negative chest x-ray and purified protein derivative (ppd) within 1 month. * understand and be able to adhere to dosing and visit schedules. * screening laboratory tests must meet protocol-specified criteria. * women and men of childbearing potential must be using adequate birth control measures and should continue such precautions for 6 months after last infusion of infliximab. exclusion criteria: * pregnant, nursing, or planned pregnancy within 6 months after last scheduled treatment. * used topical corticosteroids in previous 14 days or systemic therapy (phototherapy uvb \[uvb\], puva, cyclosporine, methotrexate) in previous 28 days, or received treatment with anti-tumor necrosis factor (tnf)-alpha monoclonal antibodies, human or murine immunoglobulins, tnf-alpha receptor fusion proteins, or other bioengineered fusion proteins. * received previous immunobiologics. * have hiv, hepatitis b or c. * recently transplanted (exception - corneal transplant \>3 months prior to first infusion) or known malignancy or history of malignancy within previous 5 years (exception - basal or squamous cell carcinoma of skin that has been treated with no evidence of recurrence). * concurrent medications that are not permitted. * congestive heart failure (chf) * use of cyclosporine or tacrolimus within 4 weeks prior to screening. * use of intramuscular (im), intravenous (iv), or oral corticosteroids within 4 weeks prior to screening. * treatment with any investigational drug within 3 months prior to screening. * allergy to murine proteins. * serious infections (hepatitis, pneumonia, pyelonephritis) in previous 3 months. * history of active tuberculosis (tb) requiring treatment within previous 3 years, or history of opportunistic infections (herpes zoster) within 2 months of screening. * current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurological or cerebral disease. * current signs or symptoms of other severe uncontrolled disease which in investigator's opinion would put the subject at an unacceptable risk. * history of current alcohol or drug abuse. * not observed designated washout periods for any of the prohibited medications in protocol.
the bshape intervention program for safety and health of survivors of cumulative trauma

Conditions: Violence; Cumulative Trauma; HIV Risk; Stress; Mental Health; Reproductive Health; Empowerment

Summary: the goal of the bshape study is to test a trauma informed, culturally tailored, multicomponent program entitled bshape (being safe, healthy, and positively empowered) for immigrant survivors of cumulative trauma.

the central hypothesis is that the bshape intervention will promote immigrant women's safety and health (e.g..,improved mental health, reduced physiological impact of stress and health inequities (especially reproductive-sexual health and hiv)), thus leading to overall empowerment. the study will: 1. conduct a feasibility and acceptability evaluation of the bshape intervention. 2. test the bshape intervention for large scale implementation in community-based clinics and programs serving immigrant women. the impact of bshape will be evaluated in comparison to usual care in promoting safety and health outcomes among immigrant women with cumulative trauma experiences at post-intervention and at 6 and 12 months follow up.

Eligibility criteria:
inclusion criteria: * 18-55 years of age * self-identify as a female * born in africa or foreign born from african descent * must have a current or past abusive romantic relationship * must be a survivor of cumulative trauma * clinically significant symptoms of ptsd and/or depression * at least one sexual hiv risk behavior exclusion criteria: * less than 18 years of age or more than age 55 * self-identify as a male * not african-born immigrant or born outside the us * is not a survivor of cumulative trauma * does not meet clinically significant criteria of ptsd and/or depression * does not report at least one sexual hiv risk behavior
noninferiority oral tranexamic acid vs intravenous administration in total hip arthroplasty

Conditions: Hemorrhage Postoperative; Total Blood Loss; Arthroplasty Complications

Summary: to find noninferiority relationship between oral and intravenous administration of tranexamic acid on peroperative and postoperative blood loss and serum concentration during primary total hip arthroplasty.

tranexamic acid is an anti-fibrinolytic drug, recommended in total hip arthroplasty to reduce peroperative and postoperative hemorrhagic complications. the original character of our study lies in the serum dosage of tranexamic acid, allowing to correlate the primary objective (blood loss) with this one. the investigators will focus on the reduction of the risks associated with the administration of intravenous medicines, the economic aspect and the ease of use.

Eligibility criteria:
inclusion criteria: - asa physical status 1, 2 and 3 scheduled for primary total hip arthroplasty exclusion criteria: * renal failure with serum creatinine level higher than 1,40 mg/dl * thromboembolic events in last 12 months before surgery * pregnancy * congenital or acquired coagulation diseases * history of gastric surgery that could lead to malabsorption * diabetic gastro-paresis
in-hospital program to systematize chest pain protocol (in-hope)

Conditions: Chest Pain; Acute Coronary Syndrome

Summary: multicenter nationwide study for analysis of the potential impact in clinical practice of early exclusion protocols for acute myocardial infarction with high sensitivity troponin t

chest pain is the main clinical complaint in emergency room visits and represents the most common symptom of acute myocardial infarction, which is the main cause of death in brazil and worldwide. although most patients with chest pain do not have a final diagnosis of ami, they remain under observation until the diagnosis of ami is excluded. the most current strategy recommended for rapid ami exclusion uses high-sensitivity cardiac troponin t at time zero and one hour later. however, some points that have not yet been properly evaluated in previous studies can be evaluated in the current study: * evaluation of the early exclusion protocol (0 -1 hour) in a brazilian population * evaluation of the early exclusion protocol (0 -1 hour) in isolation and associated with traditional risk scores (timi, grace, heart and edacs) * systematic evaluation of the early exclusion protocol (0 -1 hour) in patients without chest pain but with a pre-defined condition of suspected ami * evaluation of the prognostic value of an isolated high-sensitivity cardiac troponin t \< 5 ng/l in a diverse population.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years of age * the patient agrees and signs an informed consent form * one of the following 2 criteria: 1. acute chest pain (last episode of pain beginning \<6 hours after inclusion) or 2. syncope, dyspnea or epigastric pain without an obvious cause at the initial assessment (last episode of one of these symptoms beginning \<6 hours after inclusion) associated with at least one of the following factors: age ≥ 65 years, history of arterial disease, history of diabetes mellitus. exclusion criteria: * cardiac arrest or hypoxemia or hemodynamic instability or cardioversion during the first hour of assessment * thrombolytic therapy, primary angioplasty or other medical condition that requires hospitalization identified within one hour after the evaluation * dialysis patients * patients with trauma * myocardial revascularization or acute myocardial infarction in the last month * pregnant and breastfeeding women * patient unable to be followed for 30 days

Keywords: chest pain acute coronary syndrome troponin
predicting obesity consequences using body measure and urine metabolomics

Conditions: Non-Alcoholic Fatty Liver Disease; Body Composition; Electric Impedance

Summary: this is a prospective observational study which will recruit up to 1200 participants over a two-year period to investigate whether non-invasive methods such as bioelectrical impedance analysis parameters and urine metabolic profile are predictors for pediatric non-alcoholic liver disease.

obesity is associated with non-alcoholic fatty liver in children. currently, body mass index is used for stratification risk for non-alcoholic fatty liver disease in children. however, body mass index represents the adjusted weight status for height and may not be a perfect surrogate for body fatness. this study assumes that a combination of body measures including parameters of bioelectrical impedance analysis and hand grip strength may better represented body fatness and healthy status than body mass index. moreover, non-alcoholic fatty liver disease is strongly associated with the metabolic syndrome and non-invasive urine metabolic profile may be used to predict the disease status. the aim of this study will be to develop non-invasive methods using body measures and urine metabolic profile to predict pediatric fatty liver disease. this study will recruit 1200 apparently healthy children at year 1 to year 6 in the primary schools in taiwan within a two-year period. a series of tests including body measures, bioelectrical impedance analysis, hand grip strength and urine metabolomics by nuclear magnetic resonance will be performed in each participant. these data will be used as features to predict the results of fibroscan test.

Eligibility criteria:
inclusion criteria: * apparently healthy male or female children * students in year 1 to year 6 of primary schools exclusion criteria: * unknown liver disease * metal implant or splint * pacemaker implantation * limb defect or injury * pregnancy

Keywords: non-alcoholic fatty liver disease body composition electric impedance
zd4054 (zibotentan) or placebo plus chemotherapy in patients with advanced ovarian cancer

Conditions: Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy

Summary: the purpose of this study is to compare progression-free survival in patients with advanced ovarian cancer treated with zd4054 in combination with carboplatin+paclitaxel versus placebo in combination with carboplatin+paclitaxel.


Eligibility criteria:
inclusion criteria: * histologically proven diagnosis of: - epithelial ovarian carcinoma - fallopian tube carcinoma - primary serous peritoneal carcinoma * radiologically documented measurable disease according to recist criteria assessed by computerised tomography (ct) or magnetic resonance imaging mri) or radiologically documented non-measurable (but evaluable) disease. * advanced disease not amenable to curative surgery or radiotherapy at the time of study entry with evidence of disease recurrence or progression at least 6 months following treatment cessation of first-line platinum- containing therapy exclusion criteria: * clinical evidence of central nervous system (cns) metastases * non-epithelial ovarian cancer, including malignant mixed mullerian tumours and mucinous carcinoma of the peritoneum * tumour of borderline malignancy

Keywords: ovarian cancer chemotherapy sensitive zd4054
methylated genes in blood as biomarkers for advanced lung cancer

Conditions: Lung Cancer

Summary: the purpose of this study is to study whether the presence of lung cancer in your body can be detected by testing the blood, and if the results of these blood tests change as your tumor shrinks or grows.

this is a cooperative research project involving patients on the thoracic oncology service at memorial sloan-kettering cancer center, and the laboratory of dr. peter danenberg, professor of biochemistry and molecular biology, university of southern california / norris comprehensive cancer center in los angeles, california. the primary objectives are to measure the proportion of patients with advanced (stage iii-iv) lung cancer with methylated genes in their blood, and to determine if response to chemotherapy (complete or partial radiologic response) in patients with advanced lung cancer renders methylated genes undetectable in the blood. this research project will enroll approximately 80 patients per year over 4 years to generate a sample size of approximately 320 patients.blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.

Eligibility criteria:
inclusion criteria: * pathologically proven advanced (stage iii-iv) lung cancer * measurable and/or evaluable disease * enrollment in an mskcc protocol of experimental chemotherapy with radiologic response rate as an efficacy outcome variable, or prescription of standard chemotherapy in which the patient will be receiving routine radiological scans (every 4-8 weeks) as standard clinical practice. * signed written informed consent exclusion criteria: -none

Keywords: stage iii or iv lung cancer
the euro-craft registry

Conditions: Coronary Microvascular Disease

Summary: the euro-craft registry is a prospective, multicentric, international registry of patients undergoing functional assessment of the coronary microcirculation using the continuous thermodilution technique. angina and quality of life questionnaires (seattle angina questionnaire 19 - saq19, orbita app) will be obtained at baseline, at 6 months, and 1-year follow-up. clinical follow-up will be performed at 1 year (optionally until 5 years).


Eligibility criteria:
inclusion criteria: * age \> 18 years. * stable patients should have complaints of chest pain suspected of angina pectoris or other symptoms raising the suspicion of ihd and non-obstructive epicardial coronary arteries on invasive coronary angiography (ica, diameter stenosis of less than 50%) with an ffr \>0.80. * any other clinical scenario (including in the context of acs) prompting the physician to assess the function of the coronary microvasculature. exclusion criteria: * unable to provide consent * unstable hemodynamics * ongoing chest pain. * previous cabg * moderate to severe valvular heart disease * uncontrolled or recurrent ventricular tachycardia. * active liver disease or hepatic dysfunction, defined as ast or alt \> 3 times the uln. * comorbidity with life expectancy \<= 2 years. * severe renal dysfunction, defined as an egfr \<30 ml/min/1.73 m2. * subject is currently participating in another investigational drug or device clinical study. * presence of other anatomic or comorbid conditions, or other medical, social or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
telecare rehabilitation program in chronic low back pain with psychological retention and predominant sociability

Conditions: Low Back Pain

Summary: the present study proposes to evaluate the impact of a multidisciplinary biopsychosocial telecare rehabilitation program at the functional level in people with chronic low back pain with major psycho-behavior maintenance. the hypothesis is that a personalized program combining remote psycho-professional and physical care by digital tools improves functional evaluation in these patients.


Eligibility criteria:
inclusion criteria: * chronic low back pain (evolution of more than 3 months) * patient treated for this pathology in a multidisciplinary program * dallas score \> 50% in anxiety/depression and sociability dimensions * patient who has given free and informed consent to participate in the research * patient affiliated to a social security scheme or beneficiary of such a scheme. * patient with an internet connection at home, allowing videoconferencing and a digital tool with web cam (tablet or computer). exclusion criteria: * recent spine surgery (\< 3 months at inclusion visit) * cardiovascular risk factor contraindicating sports practice. * severe psychiatric pathology * low back pain of tumoral or inflammatory origin. * associated motor or sensory, neurological impairment. * disabling root irradiation * pregnant or breastfeeding women * patients under legal protection (guardianship, curators or safeguard of justice).